Ultrasound-Targeted Nanobubbles Show Promise in Combating Esophageal Squamous Cell Carcinoma

Strategic Insights -

Researchers from China Three Gorges University have developed an ultrasound-targeted liposome nanobubbles system that enables the precise delivery of drugs and genes to treat esophageal squamous cell carcinoma (ESCC). The system, which combines chemical immunotherapy and gene therapy, has shown significant promise in suppressing tumor growth and triggering immunogenic cell death in ESCC mouse models. In a study published in Biomaterials Research, the research team demonstrated that the system's therapeutic mechanisms, including mitochondrial dysfunction induction, immunogenic cell death, and antitumor immune activation, can be harnessed to combat ESCC.

Key Takeaways:

  • The ultrasound-targeted liposome nanobubbles system (NKP-1339/miR-142-NBs) combines chemical immunotherapy and gene therapy to treat ESCC with ultrasound-targeted microbubble destruction (UTMD).
  • The system's therapeutic mechanisms, including mitochondrial dysfunction induction, immunogenic cell death, and antitumor immune activation, can be harnessed to combat ESCC.
  • In an ESCC mouse model, NKP-1339/miR-142-NBs combined with ultrasound markedly suppressed tumor growth by 79.72% ± 0.1% compared to NB control (18.79% ± 1.29%).
  • The system triggers immunogenic cell death by exposing calreticulin on the cell membrane and altering mitochondrial fission dynamics in ESCC cells.
  • The down-regulation of PD-L1 expression by miR-142-5p reactivates CD8 T cells by relieving programmed death-1 (PD-1)/PD-L1-mediated immunosuppression, enhancing immune memory and antitumor efficacy.
  • The UTMD technique enhances tumoral accumulation and penetration of nanobubbles, improving delivery specificity and minimizing off-target effects.
  • This combined treatment strategy, including UTMD, provides a promising translational potential for ESCC therapy.

Statistics:

  • 79.72% ± 0.1% suppression of tumor growth in ESCC mouse model treated with NKP-1339/miR-142-NBs and ultrasound.
  • 18.79% ± 1.29% tumor growth in ESCC mouse model treated with NB control.
  • Significant reduction in PD-L1 expression by miR-142-5p (replaced here by actual data, if available).

Sources:

  • NewsRx. New Cancer Gene Therapy Study Findings Have Been Reported from China Three Gorges University (Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in ...). Biotech Week. August 27, 2025; p 40.
  • Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in Cancer Therapy. Biomaterials Research, 2025;29:0232.